NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $97.33 -1.06 (-1.08%) (As of 05:27 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$97.28▼$98.0950-Day Range$96.77▼$115.6052-Week Range$92.35▼$120.92Volume868,024 shsAverage Volume1.31 million shsMarket Capitalization$198.94 billionP/E Ratio11.30Dividend Yield2.50%Price Target$121.50Consensus RatingReduce Company OverviewNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More… Novartis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 58% of companies evaluated by MarketBeat, and ranked 476th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.78, and is based on no buy ratings, 7 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNovartis has only been the subject of 3 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.07% Earnings GrowthEarnings for Novartis are expected to grow by 10.07% in the coming year, from $7.65 to $8.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 11.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 11.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.54.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 6.24%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 28.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 28.86% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 6.24%, indicating that investor sentiment is improving significantly. News and Social Media1.2 / 5News Sentiment0.14 News SentimentNovartis has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Novartis this week, compared to 12 articles on an average week.Search InterestOnly 5 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesNovartis gene therapy helps children with rare muscle disorder in studyDecember 30 at 11:01 AM | reuters.comNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMADecember 30 at 12:45 AM | globenewswire.comTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…December 30, 2024 | StocksToTrade (Ad)Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025December 28 at 7:11 PM | insidermonkey.comNovartis to face whistleblower case on MS drug kickbacks: reportDecember 27 at 7:56 PM | msn.comNovartis must face claims it paid kickbacks to promote MS drug, US appeals court rulesDecember 27 at 11:19 AM | reuters.comFebruary 2025 Options Now Available For Novartis (NVS)December 21, 2024 | nasdaq.comAging-focused drug company lands new partner, potential half-billion-dollar payoutDecember 21, 2024 | bizjournals.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the start of the year. Since then, NVS stock has decreased by 3.6% and is now trading at $97.33. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, October, 29th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analysts' expectations of $12.62 billion. Novartis had a trailing twelve-month return on equity of 34.80% and a net margin of 35.96%. Does Novartis have any subsidiaries? Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK). Company Calendar Last Earnings10/29/2024Today12/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$121.50 High Stock Price Target$130.00 Low Stock Price Target$114.00 Potential Upside/Downside+24.4%Consensus RatingReduce Rating Score (0-4)1.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$8.61 Trailing P/E Ratio11.34 Forward P/E Ratio12.76 P/E Growth1.49Net Income$14.85 billion Net Margins35.96% Pretax Margin26.01% Return on Equity34.80% Return on Assets15.13% Debt Debt-to-Equity Ratio0.55 Current Ratio1.11 Quick Ratio0.90 Sales & Book Value Annual Sales$49.94 billion Price / Sales4.00 Cash Flow$11.03 per share Price / Cash Flow8.85 Book Value$22.87 per share Price / Book4.27Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$199.58 billion OptionableOptionable Beta0.56 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NYSE:NVS) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
